-
-
-
-
-
-
-
Cytokinetics (CYTK) PT Raised to $95 at RBC Capital
-
-
-
-
-
-
-
Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Ibotta, Inc. (NYSE: IBTA); and Stride, Inc. (NYSE: LRN): Grabar Law Office is In
-
-
-
-
-
-
-
Cytokinetics (CYTK) PT Raised to $82 at Barclays
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
-
-
-
-
-
-
-
Cytokinetics (CYTK) PT Lowered to $84 at Mizuho
-
-
-
-
-
-
-
Cytokinetics (CYTK) PT Lowered to $80 at Citi
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

